LigaChem Biosciences
LigaChem Biosciences (LCB) is a clinical-stage biopharmaceutical company advancing next-generation antibody-drug conjugates (ADCs) through its proprietary ConjuAll™ technology platform. LCB leverages innovative linker-payload chemistry to develop differentiated ADC candidates with enhanced efficacy, improved tolerability, and the potential to overcome resistance mechanisms. The company’s pipeline spans multiple oncology targets, supported by strategic collaborations with Amgen, Ono Pharmaceutical, Janssen (J&J), and other global partners. LCB’s lead partnered asset, LCB14/IKS014 (HER2 ADC), was named the Most Promising ADC to Watch at the 2025 World ADC Awards. Founded in 2006 and headquartered in Daejeon, South Korea, LCB is committed to delivering transformative ADC therapies to patients with cancer.
